DLBCL
56 programs · 55 companies
Programs
56
Companies
55
Trials
55
MOAs
38
PD-L1iAnti-AβCD47iKIF18AiALKiSHP2iEGFRiCGRPantBETiJAK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Preclinical | FXIa | ||
| LLY-8369 | Approved | Menin | ||
| Ceviglumide | NDA/BLA | B7-H3 | ||
| Ribosacituzumab | Approved | Cl18.2 | ||
| BMY-2495 | Phase 3 | KRASG12D | ||
| Doxacagene | Approved | PSMA | ||
| GSK-2051 | Phase 1 | PSMA | ||
| Tezecilimab | Approved | IL-23 | ||
| BII-1564 | Phase 2 | PSMA | ||
| ARG-1924 | Preclinical | DLL3 | ||
| Sematenlimab | Phase 3 | PI3Kα | ||
| COR-9566 | Approved | TYK2 | ||
| Cevinaritide | Phase 3 | AuroraA | ||
| RCK-5227 | Phase 1 | AuroraA | ||
| RDY-8278 | Phase 2/3 | PD-L1 | ||
| Semaosocimab | Phase 2/3 | HER2 | ||
| SWO-IIT-827 | Phase 2/3 | WRN | ||
| MAS-IIT-619 | Phase 2/3 | SGLT2 | ||
| DUK-IIT-253 | Phase 1 | TROP-2 | ||
| ELE-7041 | Preclinical | Menin | ||
| Tixalucimab | Phase 2 | BCL-2 | ||
| SAV-8261 | NDA/BLA | IL-23 | ||
| IMV-6044 | Phase 1/2 | BCMA | ||
| GYR-4594 | Preclinical | PLK4 | ||
| Kemaratamab | Phase 1/2 | PARP | ||
| Zanufotisoran | Phase 1/2 | ALK | ||
| Niraglumide | Phase 1/2 | BET | ||
| Voxafotisoran | Phase 2 | MDM2 | ||
| Motanaritide | Approved | FLT3 | ||
| AVE-316 | Phase 3 | SHP2 | ||
| NUW-6701 | Approved | TROP-2 | ||
| Pemitinib | Preclinical | JAK1 | ||
| 225-3371 | Approved | GIP-R | ||
| BIO-708 | Phase 2/3 | Menin | ||
| Kemafutibatinib | Phase 3 | CD38 | ||
| Lisonesiran | NDA/BLA | C5 | ||
| Talarasimod | Phase 3 | PI3Kα | ||
| Lirafotisoran | Preclinical | DLL3 | ||
| Fixatapinarof | Phase 2 | USP1 | ||
| Daratuximab | Approved | CFTR | ||
| Lisosacituzumab | Phase 1/2 | LAG-3 | ||
| GLO-9650 | Phase 2 | RET | ||
| Surazasiran | NDA/BLA | SGLT2 | ||
| KIA-7239 | Phase 2/3 | TYK2 | ||
| Ribosotorasib | Approved | HER2 | ||
| 417-3039 | Phase 2 | SHP2 | ||
| EMS-5854 | Phase 2 | KRASG12C | ||
| Dararelsin | Preclinical | PD-L1 | ||
| LAB-2279 | Phase 2 | IL-17A | ||
| APN-7734 | Phase 1 | CDK4/6 | ||
| NAT-IIT-525 | Phase 1/2 | TNFα | ||
| Sovavorutinib | Phase 2 | GIP-R | ||
| Surabrutinib | Phase 2 | RET | ||
| THE-8498 | Preclinical | PCSK9 | ||
| EUP-1431 | Phase 2 | PRMT5 | ||
| NEO-5524 | Phase 1 | PLK4 |
Trials (55)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05148814 | PFE-1085 | Preclinical | Completed |
| NCT08244331 | LLY-8369 | Approved | Terminated |
| NCT05477333 | LLY-8369 | Approved | Recruiting |
| NCT07290098 | Ribosacituzumab | Approved | Active |
| NCT03093965 | Ribosacituzumab | Approved | Recruiting |
| NCT07722438 | Ribosacituzumab | Approved | Recruiting |
| NCT06475856 | Ribosacituzumab | Approved | Active |
| NCT05262818 | BMY-2495 | Phase 3 | Not yet recr... |
| NCT05469564 | GSK-2051 | Phase 1 | Active |
| NCT06491569 | Tezecilimab | Approved | Recruiting |
| NCT08362290 | Tezecilimab | Approved | Not yet recr... |
| NCT04386940 | Tezecilimab | Approved | Completed |
| NCT05276394 | BII-1564 | Phase 2 | Completed |
| NCT04218744 | COR-9566 | Approved | Not yet recr... |
| NCT08445695 | Cevinaritide | Phase 3 | Not yet recr... |
| NCT07811972 | Cevinaritide | Phase 3 | Completed |
| NCT06016641 | Cevinaritide | Phase 3 | Active |
| NCT07179807 | RDY-8278 | Phase 2/3 | Recruiting |
| NCT06312113 | Semaosocimab | Phase 2/3 | Completed |
| NCT04205115 | SWO-IIT-827 | Phase 2/3 | Not yet recr... |